NCT02741388 - A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

September 29, 2021

Study Completion Date

September 29, 2021

Conditions

B-cell Lymphoma

Interventions

DRUG

selinexor

DRUG

Rituximab

DRUG

Dexamethasone

DRUG

Oxaliplatin

DRUG

Cisplatin

DRUG

Cytarabine

DRUG

Gemcitabine

Trial Locations (8)

Institut Jules Bordet, Brussels

CHU Dijon, Dijon

CHRU de Lille - Hôpital Claude Huriez, Lille

CHU Montpellier - Hôpital Saint Eloi, Montpellier

CHU Nancy - Hôpital de Brabois, Nancy

Hôpital Saint-Louis, Paris

CHU Bordeaux - Centre François Magendie, Pessac

Centre Henri Becquerel, Rouen